Cancer,Cell_Lines,Triple,Best_Dual,Worst_Dual,Best_Dual_Escape_Routes,Worst_Dual_Escape_Routes,Triple_Escape_Routes,Reduction_vs_Best_Dual_Pct,Reduction_vs_Worst_Dual_Pct,Dual_Median_Escape_Time,Triple_Median_Escape_Time,Escape_Time_Ratio,MannWhitney_p,Bliss_Best_Dual_Viability,Bliss_Triple_Viability
NSCLC,98,CDK6+EGFR+MAP2K1,CDK6+EGFR,CDK6+MAP2K1,73,84,73,0.0,13.1,2,2,1.0,1.35e-23,0.678,0.766
Melanoma,67,CDK6+EGFR+MAP2K1,CDK6+MAP2K1,CDK6+EGFR,45,47,45,0.0,4.3,4,4,1.0,1.70e-02,0.367,0.464
CRC,63,BRAF+EGFR+KRAS,EGFR+KRAS,BRAF+EGFR,47,73,45,4.3,38.4,3,4,1.3,3.96e-174,0.034,0.046
